• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pear Therapeutics, Sandoz ink deal for prescription digital therapeutics

April 19, 2018 By Sarah Faulkner

Pear Therapeutics revealed yesterday that it agreed to deal commercialization rights of its digital therapeutics to Novartis (NYSE:NVS) division Sandoz.

The company’s reSET substance use disorder therapy became the first prescription digital therapeutic approved by the FDA in September last year. reSET-O, a digital therapeutic designed for people suffering from opioid use disorder, is under review at the FDA.

Financial terms of the deal were not disclosed, but Boston, Mass.-based Pear Therapeutics said the agreement includes an upfront payment, R&D funding, commercial milestones and a profit split on net sales.

“After a competitive evaluation process among potential partners, Sandoz emerged as the best fit to commercialize reSET and reSET-O,” Dr. Corey McCann, president and CEO of Pear Therapeutics, said in prepared remarks.

According to the terms of the deal, Sandoz will assume responsibility for the global commercial launch of both therapies, as well as reimbursement. Pear Therapeutics plans to continue the products’ development and said it will support patients through its digital hub.

reSET, a 12-week therapy, is designed to be used alongside standard outpatient treatment for substance use disorder related to stimulants, cocaine, alcohol and cannabis, according to Pear Therapeutics. The program includes interventions and assessments through a patient’s mobile device. From there, self-reported substance use, triggers, cravings and progress are tracked to the patient’s medical provider through a clinician dashboard.

Earlier this year, Pear Therapeutics raised $50 million to fund development of its digital therapeutics. A number of investors contributed to the round, including Novartis.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Business/Financial News, Featured, mHealth (Mobile Health), Patient Monitoring, Wall Street Beat Tagged With: Novartis, peartherapeutics, sandoz

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS